BIO logo

BIO-RAD LABORATORIES-A

BIONYSE
πŸ† #884 by market capEarnings Oct 29US Equity
$357.04β–² $0.79 (+0.22%)
Live
1hβ–Ό 0.4%
24hβ–² 0.2%
7dβ–² 2.7%
14dβ–² 9.2%
30dβ–² 20.0%
1yβ–² 29.9%
🏦Market Cap
$9.61B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+0.7%
Slowing
πŸ“ŠGross Margin
51.9%
Healthy
πŸ’΅FCF Margin
13.6%
Healthy
βš–οΈP/S Ratio
3.7x
Fair
Otter Score
62
Fair

Trading Snapshot

Day Range
$355.06 – $362.73
52-Week Range
$236.73 – $359.60
Volume
$2.43B
Avg Volume
$2.64B
Shares Outstanding
26.9M
Next Earnings
Sep 13, 2026

Fundamentals Snapshot

Annual Revenue
$2.58B
Last Q Revenue
$651M
P/E Ratio
42.9
P/S Ratio
3.7x
EPS (TTM)
$8.32
Dividend Yield
0.00%

Why Investors Own BIO

  • βœ“High-growth profile β€” revenue up +27.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 40% gross margin and 22% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$2.58Bβ–² +23.0% YoY
Gross Margin (TTM)
39.6%β–² +2.8% YoY
Operating Income (TTM)
$589Mβ–² +23.0% YoY
Free Cash Flow (TTM)
$568Mβ–² +23.0% YoY

About BIO-RAD LABORATORIES-A

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
62/100

Analyst Price Target

β“˜
Average Target
$458.97
β–² +28.5% Upside
High Target$560.98
Low Target$383.05
Based on 20 analysts

Latest News & Updates